Free shipping on all orders over $ 500

Rabusertib (LY2603618)

Cat. No. M2324
Rabusertib (LY2603618) Structure
Synonym:

Rabusertib ; IC-83

Size Price Availability Quantity
2mg USD 65  USD65 In stock
5mg USD 85  USD85 In stock
10mg USD 130  USD130 In stock
50mg USD 420  USD420 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Rabusertib (LY2603618) is an effective and selective Chk1 inhibitor with an IC50 of 7 nM.

Customer Product Validations & Biological Datas
Source Oncotarget (2017). Figure 2. LY2603618
Method Clonogenic survival
Cell Lines U2OS cells
Concentrations 0, 25, 50 or 100 nM
Incubation Time 24 hours
Results An exposure time of 24 hours to the inhibitors was chosen for the clonogenic survival assays to resemble a transient delivery of such inhibitors upon in vivo single injections.
Chemical Information
Molecular Weight 436.3
Formula C18H22BrN5O3
CAS Number 911222-45-2
Solubility (25°C) DMSO 12 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Berta Laquente, et al. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

[2] Emiliano Calvo, et al. Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

[3] Darlene Barnard, et al. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models

[4] Enaksha R Wickremsinhe, et al. Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors

[5] Constance King, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

Related Checkpoint Products
CBP501 Affinity Peptide

CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents.

Chktide

Chktide is a substrate for CHK1 and CHK2.

Zn-DPA-maytansinoid conjugate 1

Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint.

CHK1-IN-7

CHK1-IN-7 is a potent human CHK1 inhibitor.

Chk2-IN-1 

Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC50s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect.

  Catalog
Abmole Inhibitor Catalog




Keywords: Rabusertib (LY2603618), Rabusertib ; IC-83 supplier, Checkpoint, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.